Omega-3/Krill, Gut–Brain–Skin Axis, and Psilocybin for Skin Aging: A Three-Part Evidence Audit

1SECTION 1 — OMEGA-3 / OMEGA-6 / KRILL OIL FOR SKIN AGING

A) What RCT evidence actually exists

The marketed claim ("omega-3 fights wrinkles") is far stronger than the actual structural-endpoint RCT base. Most rigorous marine-omega-3 skin trials measured UV erythema and inflammatory lipid mediators rather than wrinkles or elasticity — for example, Rhodes 1995 showed fish oil reduced epidermal PGE2 (n=13), and the broader n-3 PUFA literature centers on reduced UVB-erythemal sensitivity, so structural-wrinkle RCTs of pure fish oil are essentially absent.

Krill oil (strongest aging-relevant evidence). Handeland, Wakeman & Burri (Journal of Cosmetic Dermatology, 2024; PMID 39169540) ran two randomized, double-blind, placebo-controlled dose-finding pilot RCTs in healthy adults with baseline TEWL >10 and ≤24.9 g/h/m². Study 1 (n=51) used 1 g/day Superba Boost krill oil; Study 2 (n=50) used 2 g/day, over 12 weeks. Both krill groups showed statistically significant reductions in TEWL (Study 1: 14.47→13.83; Study 2: 14.25→13.02), with increases in hydration and elasticity vs placebo. TEWL effect sizes were large (Study 1 Cohen's d=0.96; Study 2 d=1.56). Critically, changes in the omega-3 index showed significant linear relationships with changes in TEWL, hydration and elasticity. Confidence: moderate, but downgraded for industry funding (both authors are employees of Aker BioMarine, the krill producer) and pilot design (no power calculation, high dropout). An additional unpublished open-label trial (n=31, 3 g/day, 13 weeks) reported reduced roughness and wrinkles.

EPA vs DHA (mechanistic human comparison). Kendall/Pilkington/Nicolaou (FASEB Journal, 2019; PMID 31518521) gave 3.5 g/day EPA (n=12) vs 3.5 g/day DHA (n=9) for 10 weeks. EPA was more efficient than DHA at reducing arachidonic-acid-derived pro-inflammatory lipids in the epidermis (epidermal EPA metabolites rose 108%); DHA more strongly affected Langerhans-cell migration. EPA raised the omega-3 index 4.86→7.67%; DHA 4.39→8.25%. This measured the skin lipidome/immunology, not wrinkles or elasticity — no EPA-vs-DHA head-to-head exists on structural skin-aging endpoints.

Fish oil / EPA UV-protection RCTs. Rhodes and colleagues established that dietary fish oil (10 g/day, 18% EPA/12% DHA) raised the minimal erythema dose but increased epidermal lipid peroxidation (PMID 8040603). A 4 g/day, 3-month EPA ethyl-ester RCT (n=28) increased MED and normalized UVB-induced PGE2. Pilkington 2013 (n=79, 5 g/day ~70% EPA, 3 months) reduced UV photoimmunosuppression (not statistically significant overall). These are photoprotection/immune endpoints, not wrinkle endpoints.

Omega-6 (GLA). Muggli (Int J Cosmet Sci, 2005; PMID 18492193) ran a randomized, double-blind, placebo-controlled trial of Efamol evening primrose oil (3×500 mg twice daily, 12 weeks) in healthy adults: skin moisture, TEWL, elasticity, firmness, fatigue resistance and roughness improved by 12.9%, 7.7%, 4.7%, 16.7%, 14.2% and 21.7% respectively vs placebo. GLA also has RCT evidence in rosacea (320 mg/day) and atopic dermatitis (improving TEWL and hydration). The omega-7 product 7-MEGA (Alaskan pollock palmitoleic acid, 500 mg twice daily) improved wrinkles, moisture and elasticity in a 101-woman RCT.

Context from meta-analysis. Yang et al. (Frontiers in Medicine, 2025;12:1582946; PMID 40761858; PROSPERO CRD42023472473), pooling 40 RCTs, concluded that "collagen, flavanols, and other polyphenol supplements have been found to alleviate skin photoaging and increase MED or overall skin elasticity (R2)," whereas "hyaluronic acid, lycopene, and carotenoids did not show any significant benefits" (polyphenol elasticity SMD=1.88, 95% CI 0.17–3.59, p=0.03). Notably, marine omega-3 did not emerge as a proven standalone wrinkle treatment in that analysis.

B) What's mechanism-only (plausible but unproven for wrinkles in humans)

• EPA inhibition of UV-induced MMP-1 (collagen-degrading enzyme) — demonstrated in human dermal fibroblasts (Kim 2005, J Lipid Res), not in a wrinkle RCT.
• Membrane phospholipid incorporation, ceramide synthesis support, and "inflammaging" reduction — biologically grounded but not tied to a measured wrinkle outcome in a clean fish-oil RCT.
• Telomere-length preservation claims — observational.

C) Dose, cost, practical sourcing

• Minimum effective dose for an aging endpoint: ~1 g/day krill oil (Handeland Study 1). Because krill is phospholipid-bound and low-concentration, this may deliver well under ~300 mg EPA+DHA. For standard fish oil there is no clean wrinkle-threshold; general skin/anti-inflammatory dosing is 1–2 g/day EPA+DHA. For context, US NHANES 2017–2018 found adult men and women consume only ~100 mg and ~90 mg/day EPA+DHA from food respectively — well below the WHO/EFSA recommended minimum of 250 mg/day — so most people have substantial headroom to supplement.
• Cost (2 g/day EPA+DHA): budget triglyceride fish oil ~$9–10/month; mid-tier IFOS-certified ~$14/month; premium (Nordic Naturals) ~$28/month. Algae-based EPA+DHA is roughly 5–8× pricier per mg (~$20–77/month).
• Sourcing/quality: Choose IFOS 5-star or USP-verified products (TOTOX ≤26, PV ≤5). Re-esterified triglyceride or phospholipid (krill) forms absorb better than ethyl esters.

D) Safety and contaminants

ConsumerLab and GOED/Nutrasource testing find essentially no mercury and only trace PCBs/dioxins in commercial fish oil — far less than eating the fish. The real quality risk is oxidation (rancidity); buy fresh, store cool/dark, smell-test. EU caps dioxins at 6 pg WHO-TEQ/g; the US has no firm federal contaminant limits (rely on IFOS/USP). On dose ceilings: the EFSA NDA Panel (January 2026 opinion) set a "safe level of intake" of 1 g/day for supplemental DHA specifically, while stating that supplemental EPA+DHA combined up to 5 g/day "do not raise safety concerns for adults"; the US FDA recommends staying under 3 g/day total EPA+DHA and, in its qualified-health-claim guidance, caps supplements at "no more than 5 g/day of EPA and DHA," citing "uncertainty about possible adverse effects on bleeding risk from consuming more than 5 grams EPA and DHA per day." Practically, 1–2 g/day is both effective and comfortably safe; mild blood-thinning and GI effects are possible at higher doses.

E) How it fits Chris's stack

• Synergy: Omega-3 supports membrane turnover for retinol users and provides anti-inflammatory "internal" support alongside collagen peptides and topical sunscreen.
• Redundancy: Krill oil already supplies EPA+DHA plus astaxanthin and choline — adding a separate fish oil is redundant; pick one marine source. If taking algae omega-3 for vegan reasons, no need for additional fish oil.
• Contraindication: Stacks additively with other blood thinners (high-dose fish oil + anticoagulants); GLA/EPO may lower seizure threshold at high doses.

F) Tier ranking and white spaces

• Tier 2 (krill/EPA for hydration, elasticity, TEWL, UV resilience; modest, partly industry-funded evidence). Fish oil for wrinkles specifically is Tier 3 (mechanism strong, structural RCT weak).
• White spaces / emerging variants: algae-based EPA+DHA (vegan, contaminant-free, but EPA-light and costly); oxidation-resistant/astaxanthin-stabilized formulations; phospholipid (krill) vs triglyceride delivery; omega-7 (7-MEGA) as an emerging wrinkle ingredient. A clean, non-industry EPA-vs-DHA facial-wrinkle RCT is the missing study.

2SECTION 2 — GUT–BRAIN–SKIN AXIS

A) What RCT evidence actually exists

This is the most evidence-rich and under-exploited of the three areas. Multiple human RCTs move skin-aging endpoints via oral gut-targeted interventions:

• Probiotics (oral, skin-aging endpoints). Lactobacillus plantarum HY7714 (Lee/Kim, J Microbiol Biotechnol): randomized, double-blind, placebo-controlled, n=110 adults aged 41–59 with dry skin/wrinkles, 1×10¹⁰ CFU/day for 12 weeks. Significant increases in facial and hand water content, significant reduction in wrinkle depth, improved gloss, and elasticity improved 13.17% at 4 weeks and 21.73% at 12 weeks vs control. Other RCTs: oral Bifidobacterium breve prevented UV-induced hydration loss/TEWL rise; a 2026 Bifidobacterium breve BB091109 postbiotic (VMK223, 500 mg/day, 12 weeks, n=29–34 women aged 40–55) reduced wrinkle depth, pore appearance and melanin while raising hydration and elasticity.
• Prebiotics. Galacto-oligosaccharide (GOS) oral RCT: 1.0 g twice daily for 12 weeks significantly increased skin hydration (corneometer +6.91 vs +2.88 a.u.), reduced TEWL (20.1→17.5 g/h/m²) and reduced wrinkle area vs placebo (PMID 28582809).
• Polyphenols → gut barrier. The MaPLE RCT (~700 mg/day total polyphenols, 8 weeks, n=66 adults ≥60) significantly reduced serum zonulin (an intestinal-permeability marker) and favored butyrate-producing F. prausnitzii. A Crohn's diet RCT (polyphenols, resistant starch, soluble fibre) reduced zonulin (259→145 ng/mL) and LBP, with changes paralleling CRP.
• Gut-barrier restorers. Bovine colostrum (500 mg/day, 20 days, n=16 athletes) significantly reduced stool zonulin and normalized lactulose/mannitol permeability (Nutrients 2017).
• Psychobiotics (stress → skin pathway). RCTs show L. plantarum PS128 + heat-treated PS23 (8 weeks, n=116 stressed adults) reduced ACTH and norepinephrine and improved anxiety/insomnia; B. breve CCFM1025 improved sleep via HPA-axis modulation. These hit the stress→cortisol→skin upstream node, though they did not measure skin.
• Collagen peptides (also benefit GI/skin). Meta-analyses (26 RCTs/1,721 patients; 23 RCTs/1,474) show hydrolyzed collagen ~2.5 g/day significantly improves skin hydration, elasticity and wrinkles.

B) What's mechanism-only in humans

• SCFA/butyrate → skin barrier: strong mechanistic and mouse data (Trompette, Mucosal Immunology 2022: oral butyrate boosts filaggrin, loricrin, involucrin, ceramide synthesis, reduces TEWL; ¹³C-butyrate reaches skin within 45 min). In vitro butyrate upregulates filaggrin/TGM1 in human keratinocytes. No human oral-butyrate wrinkle RCT yet.
• Akkermansia muciniphila: human RCTs exist (Depommier 2019, Nature Medicine, n=32, 10¹⁰/day improved metabolic markers and reduced plasma LPS; AKK-WST01 2024 T2D RCT) but skin endpoints were measured only in mouse atopic-dermatitis models (improved filaggrin + gut ZO-1). Human Akkermansia-for-skin is mechanism-only.
• F. prausnitzii, Roseburia: butyrate producers correlated with better barrier markers; no human skin RCT.
• Leaky gut → systemic inflammation → skin aging as one proven reversible chain: each link has human support (zonulin reducible by diet; LPS reducible by Akkermansia; skin endpoints movable by probiotics) but no single human trial has demonstrated the full causal chain end-to-end. This is the central honest caveat.
• FMT for skin aging: no human skin-aging trials; FMT skin work is confined to disease contexts and case reports.

C) Dose, cost, practical sourcing

• L. plantarum HY7714 ~10¹⁰ CFU/day; GOS 2 g/day; polyphenols ~700 mg/day; colostrum 500 mg/day; collagen peptides 2.5–10 g/day. Cost is generally low for prebiotics (GOS/inulin ~$10–20/month) to moderate for branded probiotics/postbiotics ($25–50/month).

D) Fit with Chris's stack

• Synergy: A prebiotic (GOS/inulin) + a wrinkle-validated probiotic strain + dietary polyphenols is a coherent, low-risk gut-skin block that also supports the omega-3 anti-inflammatory aim (omega-3 itself feeds butyrate producers). Collagen peptides double as a skin and GI-barrier support.
• Redundancy: Stacking many overlapping probiotic products is wasteful; pick one strain-specific, RCT-backed product plus a fiber/prebiotic.
• Contraindication: Caution with Akkermansia in IBD/active gut inflammation; high-FODMAP prebiotics can cause bloating.

E) Tier ranking

• Tier 1–2: GOS prebiotic and strain-specific oral probiotics (HY7714, B. breve) for hydration/elasticity/wrinkle depth — direct RCT skin endpoints, low risk, cheap.
• Tier 2: polyphenols and collagen peptides (dual gut + skin benefit).
• Tier 3: butyrate/postbiotics, Akkermansia (mechanism strong, human skin endpoints missing).
• Not yet applicable: FMT for skin aging.

F) White spaces / emerging variants

• Postbiotics (defined exopolysaccharide/cell-wall fractions, muramyl-dipeptide → NOD2 → filaggrin) are the fastest-moving frontier with first human skin RCTs appearing in 2026.
• Synbiotics (GOS + B. longum) with skin endpoints; oral butyrate or tributyrin with skin readouts; targeted Akkermansia skin-endpoint trials; vagal/HPA psychobiotics that add skin measurements would close the stress→skin loop.

3SECTION 3 — PSILOCYBIN AND PSYCHEDELIC-DERIVED COMPOUNDS FOR SKIN

A) What RCT evidence actually exists

None for skin. There are zero published human RCTs (or any human trials) of psilocybin, psilocin, or psilocybin metabolites measuring skin aging, wrinkles, or elasticity — as a primary or secondary endpoint. Legal psilocybin programs (Oregon, Canada) and clinical trials target depression, PTSD and end-of-life anxiety; none lists skin endpoints.

B) What's mechanism-only (preclinical/theoretical)

• One direct skin-aging cell study: Psilocybin in BJ-5ta human fibroblasts under high-glucose/high-lipid stress (2025, Biochemistry and Cell Biology): 10 µmol/L co-treatment preserved viability, reduced apoptosis, lowered β-galactosidase (senescence) and improved wound healing. In vitro only.
• Anti-inflammatory mechanism: Psilocybin/psilocin suppress TNF-α, IL-6, IL-1β, COX-2 and IL-8 in cell and animal models via 5-HT2A (and TrkB/AhR for BDNF) — e.g., 3D EpiIntestinal tissue, LPS-activated microglia/macrophages, mouse liver/brain inflammation. (R)-DOI (a related psychedelic) attenuates TNF-α-induced inflammation. These are inflammation models, not skin-aging models.
• Indirect pathway: psilocybin reduces depression/anxiety/stress in humans; chronic stress→cortisol→impaired skin barrier is established, so a theoretical stress-reduction→skin benefit exists — but it is entirely unproven for skin and would be slow and indirect.
• Anti-fibrotic/collagen remodeling: no psilocybin data; the fibrosis RCT field (scleroderma) uses other agents (itraconazole analogues, CB1R/iNOS inhibitors, PDRN).
• Ergot/lysergic-acid compounds: no skin RCTs.

C) Dose, cost, sourcing

Not applicable — no evidence-based oral skin protocol exists, and psilocybin is a Schedule I substance in most jurisdictions (legal only in specific supervised-therapy frameworks).

D) Fit with Chris's stack

Does not fit as a skin intervention. If pursued at all, it would be solely for mental-health/stress indications under legal supervision, with any skin benefit being speculative and downstream. No synergy or contraindication data with a skin stack exist.

E) Tier ranking

"Not yet applicable" / Tier 4. Genuinely speculative for skin: mechanism is interesting (anti-inflammatory, anti-senescence in one cell line) but there is no human skin evidence whatsoever.

F) White spaces

The only honest "white space" is preclinical: a single 2025 fibroblast senescence paper plus a coherent anti-inflammatory mechanism. If anyone runs a microdose-psilocybin trial that adds skin or inflammatory-aging biomarkers as secondary endpoints, that would be the first real datapoint. Until then, treat all "psychedelics for skin aging" marketing as hypothesis, not evidence.

4Recommendations (staged, decision-ready)

1. Now (high-confidence, low-cost): Add or consolidate to one marine omega-3 source — krill oil 1–2 g/day OR an IFOS-certified triglyceride fish oil at ~1–2 g/day EPA+DHA (favor EPA-dominant for skin anti-inflammatory effect). Pair with a wrinkle-validated oral probiotic strain (e.g., L. plantarum HY7714 ~10¹⁰ CFU/day) and a prebiotic (GOS 2 g/day). Keep collagen peptides (~2.5 g/day) for dual skin+gut benefit. Benchmark to change: if no subjective hydration/texture change by 12 weeks, reassess; consider an omega-3 index test (target ~8%).
2. Next (gut-axis optimization): Add ~700 mg/day dietary polyphenols (and consider colostrum 500 mg/day if gut-barrier concern). Threshold: if a zonulin/CRP panel is elevated, this block is higher priority.
3. Watch list (don't buy yet): oral butyrate/tributyrin and Akkermansia for skin — wait for human skin-endpoint RCTs. Postbiotic (B. breve BB091109-type) products are the emerging variant to track in 2026.
4. Do not pursue for skin: psilocybin/psychedelics — no human skin evidence; only consider via legal mental-health pathways independent of skin goals.

5Caveats

• Krill-oil skin RCTs are industry-funded pilots; effect sizes are real but should be replicated independently.
• Much gut–skin "skin-aging" mechanism rests on mouse/in-vitro butyrate and Akkermansia data; the full leaky-gut→inflammation→wrinkle chain is not proven end-to-end in one human trial.
• Many "omega-3 for wrinkles" citations actually used flaxseed/borage (ALA/GLA) or were observational — e.g., Latreille et al. (J Dermatol Sci 2013, PMID 23938188), a cross-sectional study of 2,919 SU.VI.MAX subjects aged 45–60, found "severe photoaging was found to be inversely associated with higher intake of ALA in men and with higher intake of EPA in women," which is an association, not a fish-oil RCT.
• Psilocybin-for-skin is mechanism-only; presenting it as an intervention would be misleading.